<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117775">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02050269</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO13-SE / IoxRea</org_study_id>
    <secondary_id>2013-003936-65</secondary_id>
    <secondary_id>2013-R49</secondary_id>
    <secondary_id>131229A-11</secondary_id>
    <nct_id>NCT02050269</nct_id>
  </id_info>
  <brief_title>Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study</brief_title>
  <acronym>IoxRea</acronym>
  <official_title>Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: ANSM - Agence national de sécurité du médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the feasibility of estimating the clearance of
      iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal
      function in the intensive care unit through analysis of rich iohexol plasma kinetics.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Plasma clearance of iohexol</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma clearance of iohexol in patients developping or not acute kidney injury</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between plasma iohexol clearance and kindney injury markers</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between injury and/or functional kidney dammage and subsequent acute kidney injury</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Link between plasma iohexol clearance and urinary metabolomic markers</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparaison of plasma iohexol clearance measured with 3 and 6 vs. 9 kinetic points</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Circulatory Failure</condition>
  <arm_group>
    <arm_group_label>Iohexol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>injection of 5 ml of iohexol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>Iohexol, 300 mg/mL</description>
    <arm_group_label>Iohexol</arm_group_label>
    <other_name>Iohexol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years

          -  Patient admitted to intensive care for less than 12 hours

          -  Acute circulatory failure

          -  Patient carrying an arterial catheter

          -  Informed consent obtained

          -  Affiliated to social security system

        Exclusion Criteria:

          -  Administration of iohexol the week before intensive care admission

          -  Administration of iohexol expected within 24 hours of study entry

          -  Known history of cutaneous immediate or delayed allergic reaction to the injection of
             the product

          -  Indication for albumin transfusion within 24 hours of potential inclusion in the
             study

          -  Pregnancy or breastfeeding in progress

          -  Patient under guardianship or judicial protection known at the time of inclusion

          -  Withdrawal of consent

          -  Administration of iohexol outside the study within 24 hours after administration of
             iohexol in the context of the study

          -  Administration of intravenous albumin in the 24 hours following administration of
             iohexol in the context of the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephan EHRMANN, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephan EHRMANN, MCU-PH</last_name>
    <phone>+33(0)2.47.47.98.51</phone>
    <email>stephanehrmann@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie COUDRAY</last_name>
    <phone>+33(0)2.47.47.46.64</phone>
    <email>marie.coudray@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation Polyvalente, CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan EHRMANN, MCU-PH</last_name>
    </contact>
    <investigator>
      <last_name>Stephan EHRMANN, MCU-PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
